Cardiovascular Drugs and Therapy

, Volume 4, Issue 1, pp 273–279 | Cite as

Vasodilatory effects of nisoldipine on coronary arteries—Correlation with plasma levels

  • Stefan Jost
  • Wolf Rafflenbeul
  • Birgit Mogwitz
  • Dietrich Gulba
  • Hartmut Hecker
  • Paul R. Lichtlen
Clinical and Basic Pharmacology


Vasomotion of angiographically normal and stenotic epicardial coronary arteries was analyzed up to 15 minutes after the onset of an intravenous infusion (4 minutes) of 0.5 mg (13 patients, group A) or 1 mg nisoldipine (13 patients, group B). After both doses the maximal increase of the mean diameters of normal coronary segments was achieved not before the 15th minute, averaging 11±6% in group A (p<0.001) and 18±9% in group B (p<0.001). Eleven of 15 and 8 of 9 coronary stenoses in groups A and B dilated to 5–80% and 15–70%, respectively.

The nisoldipine concentration reached maximal levels at the end of the infusion (fourth minute) with an average of 8 ±4 ng/ml and 17±7 ng/ml in groups A and B, respectively. A significant correlation between nisoldipine plasma levels and dilation of normal coronary segments was obtained only with the individual maxima of these parameters and only in group A (p<0.01). The hysteresis of the coronary dilation in relation to the drug plasma levels may be due to the high receptor affinity of nisoldipine.

In either group nisoldipine provoked a persistent increase in coronary sinus oxygen sáturation (p<0.01) and a substantial and prolonged drop in systolic and diastolic aortic pressure (p<0.001). Both doses of nisoldipine induced a rise in heart rate (p<0.01) and a slight drop in the rate-pressure product (p<0.05).

Key Words

nisoldipine coronary vasomotility coronary stenoses pharmacokinetics dihydropyridine calcium antagonists 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kazda S, Garthoff N, Meyer H, et al. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylate (nisoldipine, Bay K 5552).Drug Res 1980;30(II): 2144–2162.Google Scholar
  2. 2.
    Godfraind T, Egleme C, Finet M, et al. The actions of nifedipine and nisoldipine on the contractile activity of human coronary arteries and human cardiac tissue in vitro.Pharmacol Tocicol 1987;61:79–84.Google Scholar
  3. 3.
    Serruys PW, Suryapranata H, Planellas J, et al. Acute effects of intravenous nisoldipine on left ventricular function and coronary hemodynamics.Am J Cardiol 1985;56:140–146.PubMedGoogle Scholar
  4. 4.
    Soward AL, De Feyter PJ, Hugenholtz PG, et al. Coronary and systemic hemodynamic effects of intravenous nisoldipine.Am J Cardiol 1986;58, 1199–1203.PubMedGoogle Scholar
  5. 5.
    Schipke JD, Burkhoff D, Alexander J, Schaefer J. Sagawa K. Effect of nisoldipine on coronary resistance, contractility and oxygen consumption of the isolated blood-perfused canine left ventricle.J Pharmacol Exp Ther 1988;244:1000–1004.PubMedGoogle Scholar
  6. 6.
    Takahashi K, Taira N. Cardiovascular profiles of the calcium antagonists nisoldipine and nifedipine in the blood-perfused dog heart.Arzneimittelforschung 1986;36(II):1054–1959.PubMedGoogle Scholar
  7. 7.
    Lam J, Chaitman BR, Crean P, et al. A dose-ranging, placebo-controlled, double-blind trial of nisoldipine in effort angina: Duration and extent of antianginal effects.J Am Coll Cardiol 1985;6:447–452.PubMedGoogle Scholar
  8. 8.
    Crean PA, Waters DD, Lam J, et al. Comparative antianginal effects of nisoldipine and nifedipine in patients with chronic stable angina.Am Heart J 1987;113:261–265.PubMedGoogle Scholar
  9. 9.
    Kiowski W, Erne P, Pfisterer M, et al. Arterial vasodilator, systemic and coronary hemodynamic effects of nisoldipine in congestive heart failure secondary to ischemic or dilated cardiomyopathy.Am J Cardiol 1987;59:1118–1125.PubMedGoogle Scholar
  10. 10.
    Nienaber CA, Spielmann RP, Aschenberg W, et al. Comparison of the acute hemodynamic response to intravenous nisoldipine (Bay K 5552) and intravenous nifedipine for left ventricular dysfunction secondary to myocardial infarction.Am J Cardiol 1987;60:836–841.PubMedGoogle Scholar
  11. 11.
    Barjon JN, Rouleau JL, Bichet D, Juneau C, de Champlain J. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure.J Am Coll Cardiol 1987;3:622–630.Google Scholar
  12. 12.
    Logan SE. On the fluid mechanics of human coronary artery stenoses.IEEE Trans Biomed Eng 1975;22:327–334.PubMedGoogle Scholar
  13. 13.
    Mates RE, Gupta RI, Bell AC, et al. Fluid dynamics of coronary artery stenosis.Circ Res 1978;42:152–162.PubMedGoogle Scholar
  14. 14.
    Rafflenbeul W, Lichtlen P. Quantitative coronary angiography—evidence of a sustained increase in vascular smooth muscle tone in coronary artery stenosis.Z Kardiol 1983; 72(Suppl III):87–91.PubMedGoogle Scholar
  15. 15.
    Lichtlen P, Rafflenbeul W. Effects of calcium antagonists on fixed and dynamic obstructions in patients with severe coronary artery disease. In: Fleckenstein A, Van Breemen CR, Hoffmeister F., eds.Cardiorascular Effects of Dihydropyridine-Type Calcium Antagonists and Agonists. Berlin, Heidelberg: Springer-Verlag, 1985:381–407.Google Scholar
  16. 16.
    Ahr G, Wingender W, Kuhlmann J. Pharmacokinetics of nisoldipine. In: Hugenholtz PG, Meyer J, eds.Nisoldipine 1987. Berlin, Heidelberg: Springer-Verlag, 1987:59–66.Google Scholar
  17. 17.
    Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease: Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association.Circulation 1975;51(Suppl 5):40.Google Scholar
  18. 18.
    Reiber JHC, Kooijman CJ, Slager CJ, et al. Coronary artery dimensions from cineangiograms—methodology and validation of a computer-assisted analysis procedure.IEEE Trans Med Imag 1984;3:131–141.Google Scholar
  19. 19.
    Reiber JHC, Serruys PW, Kooijman CJ, et al. Assessment of short-, medium- and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms.Circulation 1985;71:280–288.PubMedGoogle Scholar
  20. 20.
    Reiber JHC, van Eldik-Helleman P, Visser-Akkerman N, et al. Variabilities in measurement of coronary arterial dimensions resulting from variations in cineframe selection.Cathet Cardiovasc Diagn 1988;14:221–228.PubMedGoogle Scholar
  21. 21.
    Rafflenbeul W, Urthaler F, Russell RO, et al. Dilatation of coronary artery stenoses after isosorbide dinitrate in man.Br Heart J 1980;43:546–549.PubMedGoogle Scholar
  22. 22.
    Brown BG, Bolson E, Petersen RB, et al. The mechanisms of nitroglycerin action: Stenosis vasodilatation as a major component of the drug response.Circulation 1981;64:189–197.Google Scholar
  23. 23.
    Brown BG. Response of normal and diseased epicardial coronary arteries to vasoactive drugs: Quantitative arteriographic studies.Am J Cardiol 1985;56:23E–29E.PubMedGoogle Scholar
  24. 24.
    Jost S, Rafflenbeul W, Knop I, et al. Drug plasma levels and coronary vasodilation after isosorbide dinitrate chewing capsules.Eur Heart J 1989, supplement, in press.Google Scholar
  25. 25.
    Jost S, Rafflenbeul W, Mogwitz B, et al. Coronary vasodilation with dihydropyridines—a pharmacokinetic study.Eur Heart J 1989, supplement, in press.Google Scholar
  26. 26.
    Heupler FA Jr, Proudfit WL. Nifedipine therapy for refractory coronary arterial spasm.Am J Cardiol 1979;44(5):789–803.Google Scholar
  27. 27.
    Jost S, Rafflenbeul W, Gerhardt U, et al. Influence of ionic and non-ionic radiographic contrast media on the vasomotor tone of epicardial coronary arteries.Eur Heart J 1989, supplement, in press.Google Scholar
  28. 28.
    Nellessen U, Rafflenbeul W, Jost S, et al. Diameter changes of large epicardial coronary arteries after sublingual or intravenous administration of nifedipine; correlation to plasma levels.Z Kardiol 1987;76:329–339.PubMedGoogle Scholar
  29. 29.
    Graefe KH, Ziegler R, Wingender W, et al. Plasma concentration-response relationships for some cardiovascular effects of dihydropyridines in healthy subjects.Clin Pharmacol Ther 1988;43:16–22.PubMedGoogle Scholar
  30. 30.
    Pan M, Janis RA, Triggle DJ. Comparison of the equilibrium and kinetic binding characteristics of tritiated calcium channel inhibitors, nisoldipine, nimodipine, nitrendipine and nifedipine.Pharmacologist 1983;25:202.Google Scholar
  31. 31.
    Janis RA, Shrikhande AV, Greguski R, et al. Review of nisoldipine binding studies. In: Hugenholtz PG, Meyer J, eds.Nisoldipine 1987. Berlin, Heidelberg: Springer-Verlag, 1985:27–35.Google Scholar
  32. 32.
    Heusch G, Deussen A. Nifedipine prevents sympathetic vasoconstriction distal to severe coronary stenoses.J Cardiovasc Pharmacol 1984;6:378–383.PubMedGoogle Scholar
  33. 33.
    Nakamura M, Nakagaki O, Nose Y, Fukuyama T, Kikuchi Y. Effects of nitroglycerin and dipyridamole on regional myocardial blood flow.Basic Res Cardiol 1978;73:482–496.PubMedGoogle Scholar
  34. 34.
    Warltier DC, Gross GJ, Brooks HL, et al. Coronary stealinduced increase in myocardial infarct size after pharmacologic coronary vasodilation.Am J Cardiol 1980;46:83–90.PubMedGoogle Scholar
  35. 35.
    Lichtlen P, Engel HJ. Coronary dynamics of various antianginal drugs at rest and during exercise measured by the precordial Xenon Residue Detection Technique. In: Lichtlen PR, ed.Coronary Angiography and Angina Pectoris. Stuttgart: Georg Thieme Verlag, 1976:365–377.Google Scholar
  36. 36.
    Heusch G, Guth BD, Seitelberger R, et al. Attenuation of exercise-induced myocardial ischemia in dogs with recruitment of coronary vasodilator reserve by nifedipine.Circulation 1987;75:482–490.PubMedGoogle Scholar
  37. 37.
    Warltier DC, Meils CM, Gross GJ, et al. Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (BAY K 5552), a new dihydropyridine calcium antagonist.J Pharmacol Exp Ther 1981;228:296–302.Google Scholar
  38. 38.
    Schanzenbächer P, Liebau G, Deeg P, et al. Effect of intravenous and intracoronary nifedipine on coronary blood flow and myocardial oxygen consumption.Am J Cardiol 1983; 51:712–717.PubMedGoogle Scholar
  39. 39.
    Terris S, Bourdillon PD, Cheng DT, et al. Direct cardiac and peripheral vascular effects of intracoronary and intravenous nifedipine.Am J Cardiol 1986;58:25–30.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Stefan Jost
    • 1
  • Wolf Rafflenbeul
    • 1
  • Birgit Mogwitz
    • 1
  • Dietrich Gulba
    • 1
  • Hartmut Hecker
    • 1
  • Paul R. Lichtlen
    • 1
  1. 1.Department of CardiologyHannover Medical SchoolHannover 61FRG

Personalised recommendations